Observational studyEuropean journal of clinical pharmacology2019
Drug incompatibilities in intravenous therapy: evaluation and proposition of preventive tools in intensive care and hematology units.
Observational study in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- A Network Visualization Query System for Multidrug Compatibility Based on a WeChat Mini Program: Preliminary Usability and Efficiency Evaluation.JMIR formative research · 2026Article
- SafeRx: A Canonical Pharmaceutical Knowledge Integration Framework for Multimodal Medication Safety.Bioengineering (Basel, Switzerland) · 2026Article
- Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.European journal of clinical pharmacology · 2026Observational
- Clinical pharmacist-led prevention of intravenous drug incompatibilities in an adult ICU: a prospective observational study.BMC pharmacology & toxicology · 2026Observational
- Admixture Compatibility Studies in Parenteral Formulations: Packaging, Device, and Regulatory Perspectives.AAPS PharmSciTech · 2026Review
- Stability and compatibility of phentolamine mesylate combined with furosemide in common infusion solutions for pediatric critical care.Frontiers in pediatrics · 2026Article
- Article
- Drug Incompatibilities and Complex Assemblies: Let Us Remain Vigilant!Pharmaceuticals (Basel, Switzerland) · 2025Article
- Flushing peripheral intravenous catheters: A scoping review.PloS one · 2025Article
- Evaluation of the Impact of Infusion Set Design on the Particulate Load Induced by Vancomycin-Piperacillin/Tazobactam Incompatibility.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An Assessment of Different Decision Support Software from the Perspective of Potential Drug-Drug Interactions in Patients with Chronic Kidney Diseases.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Avoiding incompatible drug pairs in central-venous catheters of patients receiving critical care: an algorithm-based analysis and a staff survey.European journal of clinical pharmacology · 2023Article
- Analysis of pharmacological interventions among hospitalised patients with COVID‑19: A focus on severe cases.Biomedical reports · 2023Article
- Peripheral intravenous catheters in the care of oncology and haematology patients.The Australian journal of cancer nursing · 2022Article
- Stability of vancomycin hydrochloride employed in antimicrobial seal solutions of central intravenous catheters.Revista latino-americana de enfermagem · 2022Article
- Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review.European journal of clinical pharmacology · 2021Review
- [Pharmacological/pharmaceutical counseling in intensive care medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2021Article
- Drug-drug interactions in polypharmacy patients: The impact of renal impairment.Current research in pharmacology and drug discovery · 2021Review
- Quantitative assessment of required separator fluid volume in multi-infusion settings.The journal of vascular access · 2020Article
- Evaluation of Incompatible Coadministration of Continuous Intravenous Infusions in a Pediatric/Neonatal Intensive Care Unit.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAGArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePhysicochemical incompatibility (PCI) between drugs infused together is frequent, but under-recognized. PCI can lead to drug inactivity, catheter occlusion, embolism or inflammatory reactions. The aims of this work were to identify most frequent and relevant drug incompatibilities and to review and develop strategies for their prevention.
methodThis was an observational prospective survey conducted between January and March 2015 in an intensive care unit (ICU) and in September 2014 in a hematology sterile unit (HSU). Drugs administered to patients were recorded and their compatibility assessed based on published compatibility data.
resultsDrug incompatibilities accounted for 12% (23/189) and 17% (116/686) of drug pairs infused in the ICU and the HSU, respectively. Pantoprazole was the most frequent drug implied in PCI. Regarding drug classes, anti-infective agents and gastrointestinal drugs were the most frequently implied. Among the incompatible pairs, 78% and 61% implicated a drug with extreme pH in the ICU and HSU, respectively. The tools proposed to reduce the frequency of PCI included: compatibility cross-tables, labeling of drugs with extreme pH and optimized administration schedules.
conclusionsGiven the frequency and the potential for severe consequences of PCI, pharmacists have a role to play in raising awareness of nurses and practitioners, and proposing adequate tools and solutions to reduce their incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.